Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes

BACKGROUND: In patients with non-cardio-embolic stroke, atorvastatin 80 mg/day reduced the relative risk of recurrent stroke by 16%, and a post hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL or more....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Stroke J
Autors principals: Amarenco, Pierre, Kim, Jong S, Labreuche, Julien, Giroud, Maurice, Lee, Byung-Chul, Mahagne, Marie-Hélène, Nighoghossian, Norbert, Simon, Tabassome, Steg, Philippe Gabriel, Touboul, Pierre-Jean, Vicaut, Eric, Yelles, Nessima, Bruckert, Eric
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2019
Matèries:
Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960693/
https://ncbi.nlm.nih.gov/pubmed/31984235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2396987319838100
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars